[go: up one dir, main page]

SI1059931T1 - Utilization of cd137 in order to promote the proliferation of peripheral monocytes - Google Patents

Utilization of cd137 in order to promote the proliferation of peripheral monocytes

Info

Publication number
SI1059931T1
SI1059931T1 SI9930165T SI9930165T SI1059931T1 SI 1059931 T1 SI1059931 T1 SI 1059931T1 SI 9930165 T SI9930165 T SI 9930165T SI 9930165 T SI9930165 T SI 9930165T SI 1059931 T1 SI1059931 T1 SI 1059931T1
Authority
SI
Slovenia
Prior art keywords
utilization
proliferation
order
promote
peripheral monocytes
Prior art date
Application number
SI9930165T
Other languages
English (en)
Slovenian (sl)
Inventor
Herbert Schwarz
Joachim Langstein
Original Assignee
Merckle Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merckle Gmbh filed Critical Merckle Gmbh
Publication of SI1059931T1 publication Critical patent/SI1059931T1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/40Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
SI9930165T 1998-07-15 1999-03-05 Utilization of cd137 in order to promote the proliferation of peripheral monocytes SI1059931T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98103859 1998-07-15
PCT/EP1999/001440 WO1999044629A2 (de) 1998-03-05 1999-03-05 Verwendung von cd137 zur förderung der proliferation peripherer monocyten
EP99910331A EP1059931B1 (de) 1998-07-15 1999-03-05 Verwendung von cd137 zur förderung der proliferation peripherer monocyten

Publications (1)

Publication Number Publication Date
SI1059931T1 true SI1059931T1 (en) 2003-04-30

Family

ID=8231533

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9930165T SI1059931T1 (en) 1998-07-15 1999-03-05 Utilization of cd137 in order to promote the proliferation of peripheral monocytes

Country Status (21)

Country Link
US (1) US6627200B1 (xx)
EP (1) EP1059931B1 (xx)
JP (1) JP2003521439A (xx)
KR (1) KR20010041624A (xx)
AT (1) ATE228371T1 (xx)
AU (1) AU747063B2 (xx)
BR (1) BR9908518A (xx)
CA (1) CA2322684A1 (xx)
CZ (1) CZ20003238A3 (xx)
DE (1) DE59903541D1 (xx)
DK (1) DK1059931T3 (xx)
EE (1) EE200000510A (xx)
ES (1) ES2188140T3 (xx)
HU (1) HUP0102046A3 (xx)
IS (1) IS1986B (xx)
NO (1) NO20004393L (xx)
NZ (1) NZ506695A (xx)
PL (1) PL343427A1 (xx)
PT (1) PT1059931E (xx)
SI (1) SI1059931T1 (xx)
WO (1) WO1999044629A2 (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003031474A2 (en) * 2001-10-04 2003-04-17 Herbert Schwarz Cd137 as a proliferation factor for hematopoietic stem cells
WO2004019866A2 (en) * 2002-08-28 2004-03-11 Immunex Corporation Compositions and methods for treating cardiovascular disease
AU2003290059A1 (en) * 2002-12-16 2004-07-09 Herbert Schwarz Use of cd137 antagonists for the treatment of tumors
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
JP5861191B2 (ja) * 2010-09-30 2016-02-16 国立大学法人 熊本大学 ミエロイド系血液細胞の製造方法
WO2014165452A1 (en) * 2013-04-03 2014-10-09 The Regents Of The University Of California Compositions and methods for inhibiting viral activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03145499A (ja) * 1989-10-31 1991-06-20 Nippon Kosei Butsushitsu Gakujiyutsu Kiyougikai ヒト単球成長因子
DE4222980A1 (de) 1992-07-13 1994-01-20 Cassella Ag Verwendung von 2-(N-(2-Aminoethyl)amino)-essigsäure-derivaten
AU6827094A (en) * 1993-05-07 1994-12-12 Immunex Corporation Cytokine designated 4-1bb ligand and human receptor that binds thereto
CA2429027C (en) * 1993-09-16 2011-04-05 Indiana University Foundation Antibodies against human receptor h4-1bb
CA2108401A1 (en) * 1993-09-27 1995-03-28 Martin Lotz Receptor induced by lymphocyte activation in imflammatory response

Also Published As

Publication number Publication date
HUP0102046A2 (hu) 2001-10-28
EP1059931B1 (de) 2002-11-27
ES2188140T3 (es) 2003-06-16
CA2322684A1 (en) 1999-09-10
DE59903541D1 (de) 2003-01-09
EP1059931A2 (de) 2000-12-20
JP2003521439A (ja) 2003-07-15
AU2932499A (en) 1999-09-20
PL343427A1 (en) 2001-08-13
AU747063B2 (en) 2002-05-09
KR20010041624A (ko) 2001-05-25
IS1986B (is) 2005-02-15
US6627200B1 (en) 2003-09-30
ATE228371T1 (de) 2002-12-15
CZ20003238A3 (cs) 2001-10-17
NZ506695A (en) 2005-01-28
HUP0102046A3 (en) 2006-02-28
EE200000510A (et) 2002-02-15
WO1999044629A2 (de) 1999-09-10
IS5613A (is) 2000-08-30
PT1059931E (pt) 2003-04-30
WO1999044629A3 (de) 2000-01-06
NO20004393L (no) 2000-10-31
BR9908518A (pt) 2000-11-21
DK1059931T3 (da) 2003-03-24
NO20004393D0 (no) 2000-09-04

Similar Documents

Publication Publication Date Title
PT1019040E (pt) Inibicao da actividade de p38-quinase por meio de arilureias
NO20021281L (no) Vaskul¶r beleggingssammensetning
MX9606386A (es) Agentes que afectan la hemostasis trombotica.
DE60014966D1 (de) Behandlung zur vermeidung von kalzifizierung für fixierte biomaterialien
ATE413386T1 (de) Ppar-gamma modulatoren
MY124214A (en) Compositions for promoting crowth
MY121031A (en) Process for preparing derivatives of the taxoid family
MXPA01007710A (es) Agente de secado por congelacion que contiene paramilon, su produccion y uso.
HK1026229A1 (en) Modified dorsal tissue affecting factor and compositions
CA2391098A1 (en) Recombinant .alpha.-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
CA2301032A1 (en) A method of preventing or treating estrogen-dependent diseases and disorders
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
ATE285177T1 (de) Thiole zur förderung des wachstumsvon hömatopoietischen vorläuferzellen
ATE190352T1 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
EP1039916B8 (fr) Utilisation d'au moins un fucane pour l'obtention d'un medicament destine au traitement des pathologies parodontales
PL316656A1 (en) Free halophantrin base for use in treating marsh-fever and compositions containing same
PL343427A1 (en) Utilization of cd137 in order to promote the proliferation of peripheral monocytes
MXPA04001720A (es) Acido nucleicos bv8 y polipeptidos con actividad mitogenica.
WO2000066732A3 (en) Laminin 8 and methods for its use
BG105779A (en) Human antibiotic proteins
MY120530A (en) Combination preparation for use in dementia
NZ514691A (en) Method to type prion proteins
ES2122912A1 (es) Inhibidores de metalocarboxipeptidasas y moleculas derivadas como agentes antitumorales.
GB9723266D0 (en) Improvements relating to treatment vessels, for example for the acetylation of lignocellulosic fibres
DE50000676D1 (de) Verwendung von orosomucoid zur herstellung einer pharmazeutischen präparation zur behandlung von pankreatitis